Navigation Links
SRI International Receives $9 Million Contract to Support National Cancer Institute PREVENT Cancer Program
Date:11/2/2015

MENLO PARK, Calif., Nov. 2, 2015 /PRNewswire/ -- SRI International has been awarded a contract of up to $9 million to provide preclinical development services to the National Cancer Institute (NCI) PREVENT Cancer Program (PCP). Under the contract, SRI will provide scientific expertise, modern testing and support facilities, and analytical instrumentation to conduct a wide variety of preclinical pharmacology and toxicology studies to evaluate potential cancer prevention drugs.

The PREVENT Cancer Drug Development Program is an NCI-supported pipeline to bring new cancer preventing interventions and biomarkers through preclinical development towards clinical trials. PREVENT enables milestone-driven progression of novel cancer preventive chemical or biological agents and biomarkers from the laboratory bench towards proof-of-principle clinical testing and registration or validation.

"We welcome the opportunity to provide preclinical toxicology and pharmacology services to support the NCI's PREVENT program," said Toufan Parman, Ph.D., D.A.B.T, director, General Toxicology, SRI Biosciences, and principal investigator for the NCI contract. "We've provided such services to the NCI for the past 23 years, and look forward to continue applying our expertise to this important work."

The current contract calls for SRI to deliver high-quality laboratory data to support NCI-PCP's efforts to develop promising therapeutic candidates such as vaccines and cancer chemopreventive agents that will inhibit, delay or reverse manifestations of cancer. SRI will be responsible for managing therapeutic candidates from conception to submission of an Investigational New Drug (IND) application to the US Food and Drug Administration. SRI has broad experience with similar studies for NCI and for many other divisions of the National Institutes of Health, as well as for private sponsors.

This effort is fully funded by the National Cancer Institute.

About SRI Biosciences
SRI Biosciences, a division of SRI International, integrates basic biomedical research with drug and diagnostics discovery and preclinical and clinical development. SRI International, a research center headquartered in Menlo Park, California, creates world-changing solutions making people safer, healthier, and more productive.

 


'/>"/>
SOURCE SRI International
Copyright©2015 PR Newswire.
All rights reserved


Related biology news :

1. CLEO: 2013 -- the Premier International Laser and Electro-Optics Event in San Jose next week
2. SPIE on global team proposing International Year of Light at United Nations
3. First international collaboration to showcase latest body of evidence of dairy health benefits
4. PETA International Science Consortium disappointed in denial of Dow appeal
5. 4th International Nanomedicine Conference
6. Efficacy of acupressure to relieve migraine nausea presented at International Headache Congress
7. MARC travel awards announced for the GSA: 19th International C. elegans Meeting
8. UChicago Celiac Disease Center to host international symposium
9. Researchers describe potential for MERS coronavirus to spread internationally
10. SmartMove, Inc. receives $200,000 grant from the Colorado Office of Economic Development and International Trade
11. International Rett Syndrome Foundation chief science officer receives prestigious military awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2019)... ... February 01, 2019 , ... uBiome, the leader in microbial ... which establishes requirements for medical laboratories to demonstrate competence to deliver timely, accurate, ... well as College of American Pathologists (CAP)-accredited, a designation given to the top ...
(Date:1/25/2019)... ... January 24, 2019 , ... uBiome, the leader in ... Microbiology at the Jackson Laboratory (JAX), to its Scientific Advisory Board. Joining the ... bring to uBiome expertise in skin microbial interactions and probiotic treatments for skin ...
(Date:1/25/2019)... ... January 24, 2019 , ... Review methodology could negatively impact ... continue to grapple with prescription drug costs, a new Pioneer Institute study ... address before deciding whether to contract with the Institute for Clinical and Economic ...
Breaking Biology News(10 mins):
(Date:1/30/2019)... YANTAI, China and SAN DIEGO (PRWEB) , ... ... ... a leading and fully integrated Contract Development and Manufacturing Organization (CDMO) serving the ... has closed its series A funding of $59.1 million backed by multiple global ...
(Date:1/30/2019)... ... January 30, 2019 , ... The Society for ... agencies to discuss best practices for laboratory automation and screening. This year the ... this year’s conference, Visikol will be at booth #345 and throughout the conference ...
(Date:1/24/2019)... , ... January 22, 2019 , ... Dr. Douglas Stramel ... Pall Veterinary Platelet Enhancement Therapy System (V-PET™) for nearly three years. ... Regenerative Cell Therapy since 2007 and began using V-PET™ 2016. V-PET™ is ...
(Date:1/20/2019)... YORK (PRWEB) , ... January 17, 2019 , ... ... clinical testing was, until recently, the exclusive purview of physicians. That's changing as ... The global direct to consumer (DTC) laboratory testing market totaled $208 million in ...
Breaking Biology Technology: